Product characteristics and pharmacokinetics of intranasal ipratropium bromide
| Autor: | Jay Grossman, Thomas MacGregor, Margaret T. Wecker, Chester C. Wood, Philip Fireman |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Male
Rhinitis Allergic Perennial medicine.drug_class medicine.medical_treatment Immunology Administration Oral Common Cold Urine Ipratropium bromide Pharmacology Absorption Pharmacokinetics Double-Blind Method Anticholinergic medicine Immunology and Allergy Humans Cross-Over Studies business.industry Ipratropium Nebulizers and Vaporizers Hemodynamics Pupil Crossover study Nasal Mucosa Nasal spray Anesthesia Injections Intravenous Nasal administration Female business medicine.drug |
| Zdroj: | The Journal of allergy and clinical immunology. 95(5 Pt 2) |
| ISSN: | 0091-6749 |
| Popis: | The in vivo absorption potential of ipratropium bromide nasal spray was evaluated in studies involving healthy volunteers (0.03%, 0.06%, and 0.12% dosage strengths) and patients with perennial rhinitis (0.03% and 0.06%) and the common cold (0.06%). The dose used was two sprays per nostril, corresponding to a total dose of 84 micrograms, 168 micrograms, and 336 micrograms for the three dosage strengths. These studies indicate that 10% or less of active drug is absorbed systemically after nasal administration based on the amount of unchanged drug excreted in urine in a 24-hour interval. In most instances, the plasma drug concentrations were undetectable. In none of these studies did plasma ipratropium concentrations reach a level where systemic anticholinergic effects are known to occur. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect